Barry J Byrne, MD, PhD, on MDA Care Centers and the Upcoming Clinical & Scientific Conference
The chief medical advisor of the Muscular Dystrophy Association discussed what seasoned clinicians and newcomers to the field alike can look forward to at the 2024 MDA Meeting.
“There are many missions of the Muscular Dystrophy Association: Both excellence in patient care and advancing multidisciplinary care, as well as assisting in discovering new therapies that improve the lives of those living with neuromuscular diseases.”
The Muscular Dystrophy Association (MDA) is an organization dedicated to serving the community of patients with neuromuscular disorders, both those with muscular dystrophies and those with other types of neuromuscular disease. A key way that the MDA has pursued this mission is through the establishment of over 150 MDA Care Centers throughout the United States. These centers serve as both centers of primary care for patients with neuromuscular diseases and as a network of research hubs for experts in the field to collaborate. The organization also annually hosts the MDA Clinical & Scientific Conference, an event that brings together both practicing clinicians and medical researchers under one roof to discuss and share ongoing research in the field.
Ahead of the 2024 meeting, which will be held on March 3-6, 2024, in Orlando, Florida, CGTLive™ spoke with Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida, to learn more about both MDA Care Centers and the upcoming conference. Byrne spoke about the goals of the organization and its activities in general, including the role of the Care Centers, and then spoke about the reasons why doctors and other healthcare professionals with an interest in neuromuscular diseases may want to attend the Clinical & Scientific Conference. He also highlighted what he is most excited about for the 2024 meeting in particular, emphasizing that attendees will be working on establishing a Gene Therapy Readiness Network. Byrne concluded the interview by encouraging early-career trainees in medicine to attend the conference, pointing out that they can benefit greatly from the firsthand chance to learn about the opportunities in neuromuscular disease care.
Click here to register for the upcoming 2024 MDA Conference.
Bendamustine Is an Effective Alternative to Fludarabine-Based Lymphodepletion in LBCL
December 7th 2024In the wake of fludarabine shortages, lemphodepletion with bendamustine was found to be an effective alternative compared for patients with large B-cell lymphoma being treated with a CD19-directed CAR T-cell therapy.
